Potential conflict of interest: Nothing to report.
Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue?†
Version of Record online: 1 MAR 2013
Copyright © 2013 the American Association for the Study of Liver Diseases
Clinical Liver Disease
Special Issue: Hepatitis B
Volume 2, Issue 1, pages 21–23, February 2013
How to Cite
Viganò, M. and Lampertico, P. (2013), Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue?. Clinical Liver Disease, 2: 21–23. doi: 10.1002/cld.161
- Issue online: 1 MAR 2013
- Version of Record online: 1 MAR 2013
- Manuscript Revised: 17 JAN 2013
- Manuscript Received: 19 DEC 2012
- 4European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012; 57: 167–185.
- 8Five years of treatment with tenofovir DF (TDF) for chronic hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis [Abstract 1375]. Hepatology 2011; 54( suppl 1): 1011A–1012A., , , , , , et al.
- 10Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology; doi: 10.1002/hep.26180., , , , , , et al.
- 14Tenofovir monotherapy suppressed viral replication in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study [Abstract 401]. Hepatology 2012; 56( suppl 1): 389A., , , , , , et al.